Sentiment Trading

BrainStorm Cell Therapeutics Inc. has made significant strides in its stem cell therapy development for neurodegenerative disorders, including FDA clearance for a Phase 3b trial, despite ongoing financial challenges.

BrainStorm Cell Therapeutics Inc. is a biotech company focused on developing autologous adult stem cell therapies for neurodegenerative disorders such as ALS, MS, and Parkinson’s disease.

BrainStorm Cell Therapeutics Inc. has rescheduled its Q1 2025 financial results release and will discuss them on an investor call on May 19, 2025, with a focus on the progress of its NurOwn stem cell therapy for ALS.